3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
61
Lymphoma, Follicular
16
Recurrence
13
Lymphoma, Non-Hodgkin
12
Lymphoma, Mantle-Cell
12
Lymphoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, B-Cell, Marginal Zone
9
Lymphoma, Large B-Cell, Diffuse
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Waldenstrom Macroglobulinemia
7
Neoplasms
7
Neoplasms, Plasma Cell
6
Lymphoma, Large-Cell, Anaplastic
5
Leukemia, Myeloid, Acute
5
Immunoblastic Lymphadenopathy
5
Lymphoma, T-Cell, Cutaneous
4
Hodgkin Disease
4
Carcinoma, Non-Small-Cell Lung
4
Sezary Syndrome
3
Prostatic Neoplasms
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Myelodysplastic Syndromes
3
Mycosis Fungoides
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, B-Cell
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia, Erythroblastic, Acute
3
Leukemia
3
Interventions
Nivolumab
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lupus Erythematosus, Systemic
×
Bortezomib
×
Clear all
NCT02102594
2019-12-03
TAVAB
Charite University, Berlin, Germany
Phase 2
Terminated
11 enrolled